The Alzheimer’s Drugs Market is anticipated to experience a compound annual growth rate (CAGR) of approximately 20% over the ...

But doctors do use one NMDA receptor antagonist: memantine (Namenda XR). It's been approved in the U.S. and Europe as a treatment for Alzheimer's disease.

Although similar alterations in NMDA receptors were detected, the differences between species underscore the need for studies on human tissue to better understand the disease.

This process largely depends on synapses, where NMDA receptors play a critical role in learning and memory. “Most NMDA receptors are found in synapses, where they enhance neuronal connections.

We used the NMDA receptor antagonist memantine to selectively target recurrent processing while minimizing non-specific side effects, a notable improvement over previous studies blocking NMDA receptors ...

This is motivated by results from Self et al 2012 where an NMDA antagonist was infused into V1. But oral memantine will, of course, have a whole-brain effect, and some of these effects are well ...

NMDA receptor antagonist NMDA receptor antagonists, like memantine (Namenda), help manage Alzheimer’s by controlling glutamate activity in the brain.

Memantine is a prescription oral tablet used to treat dementia caused by Alzheimer’s disease. Learn about side effects, warnings, dosage, and more.

More information: Ehsan Yaghmaei et al, Combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer's disease patients, Communications Medicine (2024).

The study, "Combine use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer's disease patients", was released this month in Communications Medicine, finds that ...

One example of a glutamate regulator is memantine (Namenda). Memantine is an N-methyl-D-aspartic acid (NMDA) receptor antagonist that stops calcium from invading the neurons and causing nerve injury.